All subcategories » Health Technology Assessment Report
Ivacaftor - assessment according to §35a (para. 1, sentence 10) Social Code Book V (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2016
- Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
High-frequency chest wall compression for cystic fibrosis
HTA - Health Technology Assessment Report
Details- 2016
- HAYES
Lumacaftor-ivacaftor (Orkambi) for treatment of cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2015
- HAYES
Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2015
- Hernández-Vásquez A
Ataluren (Translarna) for CFTR class I nonsense mutation mediated cystic fibrosis (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2015
- NIHR HSRIC
Ivacaftor - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment) (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2014
- IQWiG
Lumacaftor and ivacaftor combination therapy for cystic fibrosis ? first line (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2014
- NIHR HSC
Ivacaftor (Kalydeco) for an additional 8 mutations in cystic fibrosis (licence extension)
HTA - Health Technology Assessment Report
Details- 2014
- NIHR HSC
Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
HTA - Health Technology Assessment Report
Details- 2014
- Whiting P
Dornase alfa for patients with cystic fibrosis: a review of the clinical efficacy and cost-effectiveness (Structured abstract)
HTA - Health Technology Assessment Report
Details- 2013
- CADTH